Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) (AEGIS-1)
A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Ulcerative Colitis Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 1)
Sponsor: Shield Therapeutics
A PHASE3 clinical study on Inflammatory Bowel Disease and Iron Deficiency Anaemia, this trial is completed. The trial is conducted by Shield Therapeutics and has accumulated 11 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Mar 2019 — Nov 2020 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Oct 2018 — Mar 2019 [monthly]
Completed PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shield Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.